Perhexiline and hypertrophic cardiomyopathy: A new horizon for metabolic modulation

Circulation

Volumn 122, Issue 16, 2010, Pages 1547-1549

  Horowitz, John D ^a   Chirkov, Yuliy Y ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CARNITINE PALMITOYLTRANSFERASE I; METFORMIN; PERHEXILINE; RANOLAZINE; TRIMETAZIDINE; CARDIOVASCULAR AGENT; CARNITINE PALMITOYLTRANSFERASE;

ANTIINFLAMMATORY ACTIVITY; DRUG MECHANISM; EDITORIAL; ENZYME INHIBITION; HEART MUSCLE METABOLISM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LIVER TOXICITY; MYOCARDIAL DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; DRUG ANTAGONISM; DRUG EFFECT; ENERGY METABOLISM; EXERCISE TOLERANCE; HEART MUSCLE; METABOLISM; NOTE; PHYSIOLOGY;

CARDIOMYOPATHY, HYPERTROPHIC; CARDIOVASCULAR AGENTS; CARNITINE O-PALMITOYLTRANSFERASE; ENERGY METABOLISM; EXERCISE TOLERANCE; HUMANS; MYOCARDIUM; PERHEXILINE;

EID: 78049523015     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.981464     Document Type: Editorial

References (20)

1. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295-303.
2. Williams SG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J, Trusler GA. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation. 1987;76(part 2):V104-V108.
3. Faber L, Meissner A, Zeimssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart. 2000;83:326-331.
4. Melacini P, Maron BJ, Bobbo C, Tokajuk B, Zucchetto M, Thiene G, Iliceto S. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart. 2007;93:708-710.
5. Hudsmith LE, Neubauer S. Magnetic resonance spectroscopy in myocardial disease. JACC Cardiovasc Imaging. 2009;2:87-96.
6. Zhang J, Merkle H, Hendrich K, Garwood M, From AH, Urgurbil K, Bache RJ. Bioenergetic abnormalities associated with severe left ventricular hypertrophy. J Clin Invest. 1993;92:993-1003.
7. Neubauer S. The failing heart: an engine out of fuel. N Engl J Med. 2007;356:1140-1151.
8. Taha M, Lopaschuk GD. Alterations in energy metabolism in cardiomyopathies. Ann Med. 2007;39:594-607.
9. Shivu GD, Abozguia K, Phan TT, Ahmed I, Henning A, Frenneaux M. (31) P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: experiences as 3T. Eur J Radiol. 2010;73:255-259.
10. Criley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith J, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776-1782.
11. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562-1569.
12. Horowitz JD, Sia ST, Macdonald PS, Goble AJ, Louis WJ. Perhexiline maleate treatment for severe angina pectoris: correlations with pharmacokinetics. Int J Cardiol. 1986;13:219-229.
13. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, Hartley LH, Smith TW, Antman EM. Efficacy and safety of perhexiline maleate in refractory angina: a double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation. 1990;81:1260-1270.
14. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol. 1996;52:273-280.
15. Unger SA, Robinson MA, Horowitz JD. Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Aust NZ J Med. 1997;27:24-28.
16. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, Frenneaux M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005;112:3280-3288.
17. Unger SA, Kennedy JA, McFadden-Lewis K, Minerds K, Murphy GA, Horowitz JD. Dissociation between metabolic and efficiency effects of perhexiline in normoxic rat myocardium. J Cardiovasc Pharmacol. 2005;46:849-855.
18. Willoughby SR, Stewart S, Chirkov YY, Kennedy JA, Holmes AS, Horowitz JD. Beneficial effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur Heart J. 2002;23:1946-1954.
19. Kennedy JA, Beck-Oldach K, McFadden-Lewis K, Murphy GA, Wong YW, Zhang Y, Horowitz JD. Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. Eur J Pharmacol. 2006;531:13-19.
20. Shivur GN, Phan TT, Abozguia K, Ahmed I, Wagenmakers A, Henning A, Narendran P, Stevens M, Frenneaux M. Relationship between coronary microvascular dysfunction and cardiac energetics impairment in type 1 diabetes mellitus. Circulation. 2010;121:1209-1215.